Dendritic cell generation and CD4+CD25highFOXP3 + regulatory T cells in human head and neck carcinoma during radio-chemotherapy

European Journal of Medical Research

Volumn 16, Issue 2, 2011, Pages 57-62

  Schuler, Patrick J ^a,b   Borger V ^c   Bolke E ^c   Habermehls, D ^d   Matuschek, C ^c   Wild, C A ^a   Greve, J ^a   Bas, M ^e   Schilling, B ^b   Bergmann, C ^a   Trellakis, S ^a   Budach, W ^c   Gauler, T ^f   Brandau, S ^a   Lang, S ^a   Whiteside, T L ^b   Sorg, R V ^c   Hoffmann, T K ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Chemotherapy; Dendritic cell; Head and neck cancer; Regulatory T cell; Vaccination

Indexed keywords

CD83 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; CETUXIMAB; CISPLATIN; FLUOROURACIL; MITOMYCIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOCHEMOTHERAPY; CANCER RADIOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; REGULATORY T LYMPHOCYTE; AGED; ANTIGEN EXPRESSION; CANCER LOCALIZATION; CANCER STAGING; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; FLOW CYTOMETRY; LARYNX CANCER; LYMPHOCYTE SUBPOPULATION; MAXILLA SINUS CANCER; MONOCYTE; MOUTH CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARYNX CANCER; SINGLE DRUG DOSE; TUMOR ESCAPE; TUMOR IMMUNITY; UPREGULATION;

AGED; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELLS, CULTURED; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 79952785016     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Oddone N, Morgan GJ, Palme CE et al. Metastatic cutaneous squamous cell carcinoma of the head and neck: the immunosuppression, treatment, extranodal spread, and margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer. 2009;115:1883-1891.
2. Nicolette CA, Healey D, Tcherepanova I et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine. 2007;25 Suppl 2:B47-B60.
3. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104:2235-2246. (Pubitemid 39331818)
4. Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother. 2004;53:240-248.
5. Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets. 2007;7:633-642.
6. Hoffmann TK, Muller-Berghaus J, Ferris RL et al. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res. 2002;8:1787-1793. (Pubitemid 34633736)
7. Sorg RV, Ozcan Z, Brefort T et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003;26:374-383. (Pubitemid 36858722)
8. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
9. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol. 2009;123:735-746.
10. Brown K, Wong W. Diagnostic value of regulatory T cells: a new facet of a much studied cell population. Transplantation. 2008;86:1485-1491.
11. Vandenbark AA, Offner H. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? Immunology. 2008;125:1-13.
12. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759-767.
13. + regulatory T cells. Clin Cancer Res. 2008;14:2413-2420. (Pubitemid 351551075)
14. + CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007;13:2714-2721. (Pubitemid 46788040)
15. + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-648. (Pubitemid 46348738)
16. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301-6311.
17. + blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Nad Acad Sci U S A. 1996;93:2588-2592. (Pubitemid 26104391)
18. Rapp M, Ozcan Z, Steiger HJ et al. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg. 2006;105: 41-50. (Pubitemid 43979096)
19. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:3755-3762.
20. Lechmann M, Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 2002;23:273-275. (Pubitemid 34628763)
21. Whiteside TL. Tricks tumors use to escape from immune control. Oral Oncol. 2009;45:e119-e123.
22. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemomerapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 2010;11:38.
23. + Treg free of contaminating effector cells. Blood. 2009;113:827-836.
24. +CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172:4676-4680. (Pubitemid 38456386)
25. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103. (Pubitemid 26338628)
26. Kissel K, Berber S, Nockher A et al. Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion. 2006;46:818-827.
27. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother. 2008;57:1579-1587.
28. Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Med Hypotheses. 2008;71:802-804.